436 related articles for article (PubMed ID: 31278568)
1. Overcoming Challenges in Process Development of Cellular Therapies.
Highfill SL; Stroncek DF
Curr Hematol Malig Rep; 2019 Aug; 14(4):269-277. PubMed ID: 31278568
[TBL] [Abstract][Full Text] [Related]
2. Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies.
Schwab RD; Bedoya DM; King TR; Levine BL; Posey AD
Methods Mol Biol; 2020; 2086():203-211. PubMed ID: 31707678
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
[TBL] [Abstract][Full Text] [Related]
4. Driving the CAR to the Bone Marrow Transplant Program.
Dave H; Jerkins L; Hanley PJ; Bollard CM; Jacobsohn D
Curr Hematol Malig Rep; 2019 Dec; 14(6):561-569. PubMed ID: 31643018
[TBL] [Abstract][Full Text] [Related]
5. Cellular therapy: Immune-related complications.
Oved JH; Barrett DM; Teachey DT
Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
[TBL] [Abstract][Full Text] [Related]
6. Updates on CAR T-cell therapy in B-cell malignancies.
Jacoby E; Shahani SA; Shah NN
Immunol Rev; 2019 Jul; 290(1):39-59. PubMed ID: 31355492
[TBL] [Abstract][Full Text] [Related]
7. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
Yu S; Yi M; Qin S; Wu K
Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
[TBL] [Abstract][Full Text] [Related]
8. CAR T-cell therapy: Full speed ahead.
Sermer D; Brentjens R
Hematol Oncol; 2019 Jun; 37 Suppl 1():95-100. PubMed ID: 31187533
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor T cell therapy: 25years in the making.
Gill S; Maus MV; Porter DL
Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053
[TBL] [Abstract][Full Text] [Related]
10. Immunobiology of chimeric antigen receptor T cells and novel designs.
Walsh Z; Yang Y; Kohler ME
Immunol Rev; 2019 Jul; 290(1):100-113. PubMed ID: 31355496
[TBL] [Abstract][Full Text] [Related]
11. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
12. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
[TBL] [Abstract][Full Text] [Related]
13. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
14. Advances in off-the-shelf CAR T-cell therapy.
Benjamin R
Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
[No Abstract] [Full Text] [Related]
15. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
Front Immunol; 2018; 9():239. PubMed ID: 29515572
[TBL] [Abstract][Full Text] [Related]
16. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
17. Platforms for Clinical-Grade CAR-T Cell Expansion.
Mizukami A; Swiech K
Methods Mol Biol; 2020; 2086():139-150. PubMed ID: 31707673
[TBL] [Abstract][Full Text] [Related]
18. GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR.
Straetemans T; Kierkels GJJ; Doorn R; Jansen K; Heijhuurs S; Dos Santos JM; van Muyden ADD; Vie H; Clemenceau B; Raymakers R; de Witte M; Sebestyén Z; Kuball J
Front Immunol; 2018; 9():1062. PubMed ID: 29899740
[TBL] [Abstract][Full Text] [Related]
19. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
[TBL] [Abstract][Full Text] [Related]
20. CAR T cell immunotherapy for human cancer.
June CH; O'Connor RS; Kawalekar OU; Ghassemi S; Milone MC
Science; 2018 Mar; 359(6382):1361-1365. PubMed ID: 29567707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
